At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 23 enrolled
Drug / intervention
Abataceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis Who Have a History of an Inadequate Response or Intolerance to Methotrexate or Biologics
In Brief
A Phase 3 clinical trial evaluating Abatacept for Juvenile Idiopathic Arthritis. Completed, enrolled 23 participants across 13 sites.
Detailed Summary
The purpose of this study is to assess the efficacy of Abatacept after intravenous administration in Japanese children and adolescents with active juvenile idiopathic arthritis who have a history of an inadequate response or intolerance to Methotrexate or biologics
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJuvenile Idiopathic Arthritis
CountriesJapan
CollaboratorsOno Pharmaceutical Co., Ltd.
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartAug 2013
Primary CompletionNov 2015
Study CompletionJul 2018
TodayJul 2026
First PostedApr 19, 2013
Enrollment StartAug 9, 2013
Primary CompletionNov 24, 2015
Study CompletionJul 30, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.2 years ago
Interventions
Abataceptdrug